Morepen Laboratories Limited (MOREPENLAB.NS)
INR 83.7
(-0.46%)
INR 83.7
(-0.46%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 961.59 Million INR | -0.0% |
| 2022 | 386.75 Million INR | -61.96% |
| 2021 | 1.01 Billion INR | 4.73% |
| 2020 | 970.85 Million INR | 189.13% |
| 2019 | 335.79 Million INR | 16.4% |
| 2018 | 288.49 Million INR | -2.51% |
| 2017 | 295.91 Million INR | 25.72% |
| 2016 | 235.37 Million INR | 83.89% |
| 2015 | 127.99 Million INR | 498.12% |
| 2014 | 21.4 Million INR | 177.26% |
| 2013 | -27.7 Million INR | 86.5% |
| 2012 | -205.2 Million INR | 13.23% |
| 2011 | -236.5 Million INR | 49.62% |
| 2010 | -469.44 Million INR | -655.1% |
| 2009 | -62.17 Million INR | 85.11% |
| 2008 | -417.58 Million INR | 23.89% |
| 2007 | -548.64 Million INR | 65.38% |
| 2006 | -1.58 Billion INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 361.67 Million INR | 338.93% |
| 2023 Q2 | 212.56 Million INR | 45.26% |
| 2023 Q3 | 319.9 Million INR | 50.5% |
| 2023 Q4 | 82.4 Million INR | -74.24% |
| 2023 Q1 | 146.33 Million INR | 77.58% |
| 2023 FY | 386.75 Million INR | -0.0% |
| 2022 Q4 | 82.4 Million INR | -8.37% |
| 2022 Q3 | 89.93 Million INR | -43.12% |
| 2022 FY | 386.75 Million INR | -61.96% |
| 2022 Q1 | 56.3 Million INR | -54.31% |
| 2022 Q2 | 158.11 Million INR | 180.83% |
| 2021 FY | 1.01 Billion INR | 4.73% |
| 2021 Q2 | 373.63 Million INR | 22.61% |
| 2021 Q3 | 215.21 Million INR | -42.4% |
| 2021 Q1 | 304.74 Million INR | 13.9% |
| 2021 Q4 | 123.23 Million INR | -42.74% |
| 2020 Q2 | 271.69 Million INR | 40.28% |
| 2020 Q1 | 193.67 Million INR | 75.73% |
| 2020 FY | 970.85 Million INR | 189.13% |
| 2020 Q4 | 267.55 Million INR | 12.45% |
| 2020 Q3 | 237.93 Million INR | -12.42% |
| 2019 Q3 | 108.17 Million INR | 164.98% |
| 2019 FY | 335.79 Million INR | 16.4% |
| 2019 Q4 | 110.2 Million INR | 1.88% |
| 2019 Q1 | 76.59 Million INR | -27.01% |
| 2019 Q2 | 40.82 Million INR | -46.7% |
| 2018 Q4 | 104.92 Million INR | 17.64% |
| 2018 FY | 288.49 Million INR | -2.51% |
| 2018 Q3 | 89.19 Million INR | 27.89% |
| 2018 Q1 | 24.63 Million INR | -63.83% |
| 2018 Q2 | 69.74 Million INR | 183.14% |
| 2017 Q2 | 110.74 Million INR | 768.72% |
| 2017 FY | 295.91 Million INR | 25.72% |
| 2017 Q3 | 104.31 Million INR | -5.81% |
| 2017 Q4 | 68.1 Million INR | -34.71% |
| 2017 Q1 | 12.74 Million INR | 0.0% |
| 2016 FY | 235.37 Million INR | 83.89% |
| 2015 FY | 127.99 Million INR | 498.12% |
| 2014 FY | 21.4 Million INR | 177.26% |
| 2013 FY | -27.7 Million INR | 86.5% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2012 FY | -205.2 Million INR | 13.23% |
| 2012 Q2 | - INR | 0.0% |
| 2011 FY | -236.5 Million INR | 49.62% |
| 2010 FY | -469.44 Million INR | -655.1% |
| 2009 FY | -62.17 Million INR | 85.11% |
| 2008 FY | -417.58 Million INR | 23.89% |
| 2007 FY | -548.64 Million INR | 65.38% |
| 2006 FY | -1.58 Billion INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sigachi Industries Limited | 571.8 Million INR | -68.17% |
| Ind-Swift Limited | 142.31 Million INR | -575.693% |
| Bajaj HealthCare Limited | -837.93 Million INR | 214.759% |
| Sakar Healthcare Limited | 116.7 Million INR | -723.929% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 96.969% |
| Innova Captab Limited | 943.45 Million INR | -1.924% |
| Divi's Laboratories Limited | 16 Billion INR | 93.99% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 40.462% |
| Mankind Pharma Limited | 19.12 Billion INR | 94.973% |
| Sequent Scientific Limited | -358.69 Million INR | 368.086% |
| Wanbury Limited | 559.56 Million INR | -71.848% |
| Laurus Labs Limited | 1.6 Billion INR | 40.106% |
| Nectar Lifesciences Limited | 49.95 Million INR | -1825.123% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 79.579% |
| Alembic Limited | 2.68 Billion INR | 64.202% |
| Hikal Limited | 696 Million INR | -38.161% |
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 84.385% |
| Neuland Laboratories Limited | 3 Billion INR | 67.955% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 82.6% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 106.404% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 28.468% |
| Themis Medicare Limited | 435.23 Million INR | -120.936% |
| RPG Life Sciences Limited | 876.6 Million INR | -9.696% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 97.508% |
| Lupin Limited | 19.14 Billion INR | 94.977% |
| Amrutanjan Health Care Limited | 449.72 Million INR | -113.819% |
| Wockhardt Limited | -4.63 Billion INR | 120.769% |
| Vaishali Pharma Limited | 7.18 Million INR | -13275.977% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 55.667% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | -328.081% |
| Jubilant Pharmova Limited | 771 Million INR | -24.721% |
| FDC Limited | 3.05 Billion INR | 68.495% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 98.273% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | -558.566% |
| Eris Lifesciences Limited | 3.91 Billion INR | 75.468% |
| Venus Remedies Limited | 284.9 Million INR | -237.512% |
| ZIM Laboratories Limited | 172.46 Million INR | -457.565% |
| Bliss GVS Pharma Limited | 754.54 Million INR | -27.442% |
| Par Drugs and Chemicals Limited | 145.01 Million INR | -563.126% |
| Caplin Point Laboratories Limited | 4.57 Billion INR | 78.963% |
| Shilpa Medicare Limited | 318.74 Million INR | -201.686% |
| Albert David Limited | 754.2 Million INR | -27.499% |
| Ajanta Pharma Limited | 8.16 Billion INR | 88.218% |
| Hester Biosciences Limited | 188.89 Million INR | -409.079% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 67.977% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 116.948% |
| Gufic Biosciences Limited | 861.35 Million INR | -11.638% |
| Windlas Biotech Limited | 581.87 Million INR | -65.26% |
| Procter & Gamble Health Limited | 2 Billion INR | 52.154% |
| Aarey Drugs & Pharmaceuticals Limited | 46.83 Million INR | -1953.09% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | 1159.999% |
| Granules India Limited | 4.05 Billion INR | 76.275% |
| Aarti Drugs Limited | 1.71 Billion INR | 43.903% |
| Bal Pharma Limited | 73.92 Million INR | -1200.829% |
| Alkem Laboratories Limited | 17.95 Billion INR | 94.645% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 98.996% |
| Lincoln Pharmaceuticals Limited | 933.04 Million INR | -3.06% |
| Medicamen Biotech Limited | 109.31 Million INR | -779.699% |
| Unichem Laboratories Limited | -704.74 Million INR | 236.447% |
| Bafna Pharmaceuticals Limited | 73.47 Million INR | -1208.672% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | -13458.926% |
| Valiant Laboratories Limited | 3.19 Million INR | -29987.578% |
| Orchid Pharma Limited | 921.66 Million INR | -4.333% |
| Medico Remedies Limited | 82.9 Million INR | -1059.825% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 77.157% |
| Ipca Laboratories Limited | 5.47 Billion INR | 82.432% |
| Brooks Laboratories Limited | -195.91 Million INR | 590.815% |
| Syncom Formulations (India) Limited | 253.14 Million INR | -279.865% |
| Piramal Enterprises Limited | -16.83 Billion INR | 105.712% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 94.195% |
| NATCO Pharma Limited | 13.88 Billion INR | 93.074% |
| Suven Life Sciences Limited | -1.05 Billion INR | 191.514% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | 587.419% |
| Strides Pharma Science Limited | -706.14 Million INR | 236.177% |
| Indoco Remedies Limited | 984.6 Million INR | 2.336% |
| Alpa Laboratories Limited | 167.76 Million INR | -473.182% |
| Lasa Supergenerics Limited | -217.3 Million INR | 542.509% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 124.834% |